VMTH.F Stock Overview
Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Venus Medtech (Hangzhou) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.011 |
| 52 Week High | HK$0.64 |
| 52 Week Low | HK$0.011 |
| Beta | 0.54 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.86% |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| VMTH.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | 20.8% | 31.6% |
Return vs Industry: Insufficient data to determine how VMTH.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how VMTH.F performed against the US Market.
Price Volatility
| VMTH.F volatility | |
|---|---|
| VMTH.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VMTH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VMTH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 865 | Lin Haosheng Lim | www.venusmedtech.com |
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, and VenusA-Pro; and VenusP-Valve is a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension.
Venus Medtech (Hangzhou) Inc. Fundamentals Summary
| VMTH.F fundamental statistics | |
|---|---|
| Market cap | US$314.99m |
| Earnings (TTM) | -US$703.75m |
| Revenue (TTM) | US$491.37m |
0.0x
P/S Ratio0.0x
P/E RatioIs VMTH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VMTH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥491.37m |
| Cost of Revenue | CN¥102.17m |
| Gross Profit | CN¥389.21m |
| Other Expenses | CN¥1.09b |
| Earnings | -CN¥703.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 79.21% |
| Net Profit Margin | -143.22% |
| Debt/Equity Ratio | 24.2% |
How did VMTH.F perform over the long term?
See historical performance and comparison